2026-04-14T03:53:53Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/111622025-10-24T10:29:15Zcom_2072_378070com_2072_378040col_2072_378092

Real-world experience of IL-17Ai drug survival in a large cohort of axial spondyloarthritis and psoriatic arthritis weddell, jake Aung Din, B Naw Ra Harrison, Stephanie McGonagle, Dennis barr, andrew Michelena Vegas, Xabier Institut Català de la Salut [Weddell J, Harrison SR, McGonagle D] NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK. Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Chapel Allerton Hospital, Leeds, UK. [Din NRA] Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Chapel Allerton Hospital, Leeds, UK. [Michelena X] Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK. Servei de Reumatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Barr A] Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK. Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Chapel Allerton Hospital, Leeds, UK Vall d'Hebron Barcelona Hospital Campus Anticossos monoclonals - Ús terapèutic Artritis psoriàsica - Tractament Espondiloartritis anquilosant - Tractament DISEASES::Musculoskeletal Diseases::Bone Diseases::Spinal Diseases::Spondylitis::Spondylarthritis::Spondylarthropathies::Spondylitis, Ankylosing DISEASES::Musculoskeletal Diseases::Musculoskeletal Diseases::Joint Diseases::Arthritis::Musculoskeletal Diseases::Joint Diseases::Arthritis::Spondylarthritis::Spondylarthropathies::Arthritis, Psoriatic CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal ENFERMEDADES::enfermedades musculoesqueléticas::enfermedades óseas::enfermedades de la columna vertebral::espondilitis::espondiloartritis::espondiloartropatías::espondilitis anquilosante ENFERMEDADES::enfermedades musculoesqueléticas::enfermedades musculoesqueléticas::artropatías::artritis::enfermedades musculoesqueléticas::artropatías::artritis::espondiloartritis::espondiloartropatías::artritis psoriásica COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales Axial spondyloarthritis; Drug survival; Psoriatic arthritis Espondiloartritis axial; Supervivencia de los medicamentos; Artritis psoriásica Espondiloartritis axial; Supervivència dels medicaments; Artritis psoriàsica Objective The aim was to assess the use and drug survival of IL-17Ai in a real-world cohort of axial SpA (axSpA) and PsA patients. Methods Patients ever commenced on an IL-17Ai (secukinumab or ixekizumab) for axSpA or PsA at the Leeds Specialist Spondyloarthritis Service were identified. Demographics, IL-17Ai treatment length and reason for cessation were collected. Drug survival data were plotted as a Kaplan–Meier curve, with log rank test of median survival compared between axSpA and PsA. Cox regression analysis was performed to investigate the relationship between diagnosis and length of drug survival. Results In total, 228 patients (91 axSpA and 137 PsA) were exposed to IL-17Ai. Drug survival for all patients at 12 months was 69% (95% Confidence Interval (CI) 63, 75%) and at 24 months 60% (95% CI 54, 67%). In axSpA and PsA, drug survival at 12 months was 63% (CI 54, 74%) and 73% (CI 66, 81%), respectively, and at 24 months it was 53% (CI 44, 65%) and 65% (CI 57, 75%), respectively. Median survival did not differ significantly between both diseases (log rank test 0.65). There was no association between diagnosis and survival (hazard ratio 0.92, 95% CI 0.63, 1.33), including when adjusting for age, previous biologic DMARD usage and sex (hazard ratio 0.89, 95% CI 0.61, 1.13). Conclusion This is the first study, to our knowledge, to analyse and compare real-world IL-17Ai drug survival in patients with axSpA and PsA from a single centre. We demonstrate that there is no difference in IL-17Ai survival rates and no relationship between diagnosis and drug survival. These results contribute to the body of real-world evidence confirming the role of IL-17Ai in the management of axSpA and PsA. 2024-03-06T07:40:27Z 2024-03-06T07:40:27Z 2024-02-15 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Weddell J, Ra N, Din A, Harrison SR, Michelena X, Mcgonagle D, et al. Real-world experience of IL-17Ai drug survival in a large cohort of axial spondyloarthritis and psoriatic arthritis. Rheumatol Adv Pract. 2024 Feb 15;8(1):rkae018. 2514-1775 https://hdl.handle.net/11351/11162 10.1093/rap/rkae018 38435412 http://hdl.handle.net/11351/11162 eng Rheumatology Advances in Practice;8(1) https://doi.org/10.1093/rap/rkae018 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess application/pdf Oxford University Press Scientia